Changeflow GovPing Healthcare & Life Sciences PRP vs Betamethasone Upper Trapezius Myofascial...
Routine Notice Added Final

PRP vs Betamethasone Upper Trapezius Myofascial Pain Study

Favicon for clinicaltrials.gov ClinicalTrials.gov - Phase 4 Trials
Detected
Email

Summary

ClinicalTrials.gov has registered a new randomized, Phase 4 clinical trial (NCT07547605) comparing platelet-rich plasma (PRP) injections against betamethasone for the treatment of myofascial pain syndrome affecting the upper trapezius muscle. The trial's structured record includes eligibility criteria, intervention details, and outcome measures. No recruitment status, enrollment figure, or anticipated completion date was provided in the registration entry.

Published by NIH on clinicaltrials.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors ClinicalTrials.gov - Phase 4 Trials for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 3 changes logged to date.

What changed

NIH's ClinicalTrials.gov has posted a new Phase 4 clinical trial registration (NCT07547605) for a randomized study comparing PRP injections to betamethasone for upper trapezius myofascial pain. The registration entry captures the study's title, condition (myofascial pain syndrome, upper trapezius), and intervention comparison (platelet-rich plasma vs. betamethasone). The record is structured per FDAAA 801 requirements for applicable clinical trials.

Affected parties — clinical investigators, trial sponsors, and referring clinicians — should note the trial's existence for patient-referral and competitive-landscape awareness. This is an informational registration event; it does not itself impose compliance obligations beyond standard FDAAA 801 trial-registration obligations that already apply to the sponsoring entity.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Show glossary

Get daily alerts for ClinicalTrials.gov - Phase 4 Trials

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Clinical investigators Healthcare providers
Industry sector
6211 Healthcare Providers
Activity scope
Clinical trial registration Comparative efficacy study
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Pharmaceuticals Medical Devices

Get alerts for this source

We'll email you when ClinicalTrials.gov - Phase 4 Trials publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!